Invention Grant
- Patent Title: Indanes as NRF2 activators
-
Application No.: US17056495Application Date: 2019-05-16
-
Publication No.: US11643407B2Publication Date: 2023-05-09
- Inventor: Jeffrey K. Kerns
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Applicant Address: GB Brentford
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford
- Agent Nora L. Stein
- Priority: IT 2018000006105 2018.06.07
- International Application: PCT/IB2019/054607 2019.05.16
- International Announcement: WO2019/224667A 2019.11.28
- Date entered country: 2020-11-18
- Main IPC: C07D417/10
- IPC: C07D417/10 ; C07D249/04 ; A61K9/00
Abstract:
The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I) or Formula (II), and pharmaceutically acceptable salts thereof:
Public/Granted literature
- US20210198249A1 INDANES AS NRF2 ACTIVATORS Public/Granted day:2021-07-01
Information query
